Login / Register 
United States ($) USD
Austria (€) EUR
Belgium (€) EUR
Finland (€) EUR
France (€) EUR
Germany (€) EUR
Ireland (€) EUR
Japan (¥) JPY
Luxembourg (€) EUR
Netherlands (€) EUR
Switzerland (CHF) CHF
United Kingdom (£) GBP
- Other Names
- Interleukin-34
- Ave. Rating
- Submit a Review
- Product Citations
- publications
-
GMP recombinant human IL-34 induces MCP-1 (CCL2) production in human peripheral blood mononuclear cells (PBMC) in a dose-dependent manner. The ED50 for this effect is 4 - 20 ng/mL. -
Stability Testing for GMP Recombinant Human IL-34. Human IL-34 was aliquoted in 10mM Na2HPO4, 0.5M NaCl, pH 7.4 at 0.2 mg/mL. One aliquot was frozen and thawed four times (4x Freeze/Thaw) and compared to the control that was kept at 4°C (Control). The samples were tested for their ability to induce MCP-1 (CCL2) production in human peripheral blood mononuclear cells (PBMC) in a dose-dependent manner. The ED50 for this effect is 4 - 20 ng/mL.
| Cat # | Size | Price | Quantity Check Availability | Save | ||
|---|---|---|---|---|---|---|
| 577916 | 100 µg | 2052€ | ||||
| 577914 | 25 µg | 658€ | ||||
Human IL-34 shares amino acid sequence similarity of 99.6%, 72% and 71% with chimpanzee, rat, and mouse IL-34, respectively. The IL-34 gene is syntenic in the human, chimpanzee, rat, and mouse genomes. IL-34 shows lack of consensus in the structural domain or motif, and does not share any sequence homology with M-CSF but it still binds to the CSFR. These two cytokines are not identical in biological activity and signal activation. IL-34 and CSF show an equivalent ability to support cell growth or survival. However, these cytokines have differing ability to induce the production of chemokines (MCP-1 and eotaxin-2) in primary macrophages, the morphological change in TF-1-fms cells, and the migration of J774A.1 cells. The use of monoclonal antibodies against the CSFR suggests a differential domain binding in the receptor to IL-34 and CSF and, as a result, different bioactivities and signal activation kinetics/strength are produced for these cytokines. High levels of IL-34 has been detected in serum of patients with polycystic ovary syndrome and in patients with acute ischemic stroke.
Product DetailsProduct Details
- Source
- Human IL-34, amino acid (Asn21-Pro242) (Accession: # NM_152456.2), with carboxy terminus 10H tag, was expressed in CHO cells.
- Molecular Mass
- The 235 amino acid recombinant protein has a predicted molecular mass of 26.7 kD. The DTT-reduced protein migrates at approximately 40 kD, and the non-reduced protein migrates with slightly greater mobility by SDS-PAGE. The predicted N-terminal amino acid is Asn.
- Purity
- > 95%, as determined by Coomassie stained SDS-PAGE.
- Formulation
- 0.1 µm filtered protein solution is in 10mM Na2HPO4, 0.5M NaCl, pH 7.4.
- Endotoxin Level
- Less than 0.1 EU per µg cytokine as determined by the LAL method.
- Concentration
- 25 µg and 100 µg sizes are at 0.5 mg/mL.
- Storage & Handling
- Unopened vial can be stored between 2°C and 8°C for up to 2 weeks, at -20°C for up to six months, or at -70°C or colder until the expiration date. For maximum results, quick spin vial prior to opening. The protein can be aliquoted and stored at -20°C or colder. Stock solutions can also be prepared at 50 - 100 µg/mL in appropriate sterile buffer, carrier protein such as 0.2 - 1% endotoxin-free BSA or HSA can be added when preparing the stock solution. Aliquots can be stored between 2°C and 8°C for up to one week or stored at -20°C or colder for up to 3 months. Avoid repeated freeze/thaw cycles.
- Activity
- Human IL-34 induces MCP-1 (CCL2) production in human peripheral blood mononuclear cells (PBMC) in a dose-dependent manner. The ED50 for this effect is 4 - 20 ng/mL.
- Application
-
Bioassay
- Application Notes
-
BioLegend carrier-free recombinant proteins provided in liquid format are shipped on blue-ice. Our comparison testing data indicates that when handled and stored as recommended, the liquid format has equal or better stability and shelf-life compared to commercially available lyophilized proteins after reconstitution. Our liquid proteins are verified in-house to maintain activity after shipping on blue ice and are backed by our 100% satisfaction guarantee. If you have any concerns, contact us at tech@biolegend.com.
- Disclaimer
-
GMP Recombinant Proteins. BioLegend GMP recombinant proteins are manufactured in a dedicated GMP facility and compliant with ISO 13485:2016. For research or ex vivo cell processing use. Not for use in diagnostic or therapeutic procedures. Our processes include:
- Batch-to-batch consistency
- Material traceability
- Documented procedures
- Documented employee training
- Equipment maintenance and monitoring records
- Lot-specific certificates of analysis
- Quality audits per ISO 13485:2016
- QA review of released products
BioLegend GMP recombinant proteins are manufactured and tested in accordance with USP Chapter 1043, Ancillary Materials for Cell, Gene and Tissue-Engineered Products and Ph. Eur. Chapter 5.2.12.
Antigen Details
- Structure
- Homodimer
- Distribution
-
IL-34 mRNA is expressed in different tissues, including spleen, heart, brain, lung, liver, kidney, thymus, testes, ovary, small intestine, prostate, and colon.
- Function
- IL-34 increases monocyte's viability, induces macrophage proliferation, and synergizes with other cytokines to generate macrophages and osteoclasts from cultured progenitors. IL-34 promotes the formation of the colony-forming unit-macrophage (CFU-M) in human bone marrow culture. IL-34 supports RANKL-induced osteoclastogenesis by promoting the adhesion and proliferation of osteoclast progenitors. Human IL-34 promotes the osteoclast differentiation from peripheral blood mononucleated cells. In addition, systematic administration of IL-34 to mouse increases the number of CD11b+ cells and reduces bone mass. IL-1β and TNF-α induce the expression of interleukin-34 mRNA in osteoblast. IL-34 is induced in macrophages infected with equine infectious anemia virus (EIAV).
- Interaction
- Macrophages, monocytes, myeloid cells
- Ligand/Receptor
- CSF-1R
- Bioactivity
- Induces cytokine production in PBMCs.
- Biology Area
- Immunology, Innate Immunity, Stem Cells
- Molecular Family
- Cytokines/Chemokines
- Antigen References
-
- Clanchy F, et al. 2006. J Leukoc Biol. 79:757-66.
- Lin H, et al. 2008. Science. 320:807-11.
- Chihara T, et al. 2010. Cell Death Differ. 17:1917-27.
- Wei S, et al. 2010. J Leukoc Biol. 88:495-505.
- Eda H, et al. 2010. Cytokine. 52:215-20.
- Covaleda L, et al. 2010. Virology. 397:217-23.
- Chen Z, et al. 2011. PLoS One. 6:e18689.
- Cai H, et al. 2022. J Obstet Gynecol Res. 48:973.
- Huang X, et al. 2021. J Neuroimminol. 358:577652.
- Gene ID
- 146433 View all products for this Gene ID
- UniProt
- View information about IL-34 on UniProt.org
Follow Us